Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
ABUSArbutus Biopharma(ABUS) ZACKS·2024-08-01 21:40

Arbutus Biopharma (ABUS) came out with a quarterly loss of 0.11pershareversustheZacksConsensusEstimateofalossof0.11 per share versus the Zacks Consensus Estimate of a loss of 0.10. This compares to loss of 0.10pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof−100.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -10%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of 0.10 per share when it actually produced a loss of $0.10, delivering no surprise.Over the last four quarters, the company has ...